What the 'Pathway Approach' Can Do to Improve Health Outcomes, Reduce Testing Delays For Cancer Care
Dr. Yuri Fesko of Quest Diagnostics says the "pathways approach" helped one health system speed the time between diagnosis and targeted treatment for lung cancer by as much as a month for some patients. This is the second part of a three-part video series.
Editor of Managed Healthcare Executive, Briana Contreras, speaks with Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, about why shortening the gap of time it takes to receive a cancer diagnosis and getting the treatment for it is critical to ensuring better patient outcomes. Dr. Fesko also shared steps hospitals, health systems and physicians can take now to reduce testing delays, improve outcomes and lower costs of care. These steps include using an innovative “pathways” approach that helped one health system speed the time between diagnosis and targeted treatment for lung cancer by as much as a month for some patients.
Analysis Finds Brukinsa May Provide Costs Savings Over Imbruvica in CLL
April 14th 2025In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
Rutgers Cancer Institute Reviews Guidelines for Managing Blood Cancers During Pregnancy
April 8th 2025About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer, accounting for 1 in 10,000 pregnancies. The most common pregnancy-related leukemias are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML).
Read More
Microplastics, Diet and More: What’s Causing Early-Onset Cancer?
March 18th 2025In a February 2025 Time magazine cover story, Jamie Ducharme reports on this atypical and disquieting trend. Ducharme cites a 79% increase in early-onset cancer diagnoses and a 28% increase in cancer-related deaths in this age group from 1990 to 2019.
Read More
